Follicular Thyroid Cancer
14
2
5
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.1%
1 terminated out of 14 trials
87.5%
+0.9% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (14)
Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion
Studies on Tumors of the Thyroid
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC
Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors